α- and β-secretase:: profound changes in Alzheimer's disease

被引:152
|
作者
Tyler, SJ
Dawbarn, D
Wilcock, GK
Allen, SJ [1 ]
机构
[1] Univ Bristol, Bristol Royal Infirm, Mol Neurobiol Unit, URCN Care Elderly, Bristol BS2 8HW, Avon, England
[2] Frenchay Hosp, Dept Care Elderly, Bristol BS16 1LE, Avon, England
关键词
Alzheimer's disease; alpha-secretase; amyloid; apolipoprotein E; beta-secretase; BACE; choline acetyltransferase; TACE;
D O I
10.1016/S0006-291X(02)02635-9
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The amyloid plaque, a neuropathological hallmark of Alzheimer's disease, is produced by the deposition of beta-amyloid (Abeta) peptide, which is cleaved from Amyloid Precursor Protein (APP) by the enzyme beta-secretase. Only small amounts of Abeta form in normal brain; more typically this is precluded by the processing of APP by alpha-secretase. Here, we describe a decrease in alpha-secretase (81% of normal) and a large increase in beta-secretase activity (185%) in sporadic Alzheimer's disease temporal cortex. Since alpha-secretase is present principally in neurons known to be vulnerable in Alzheimer's disease, and there is known competition between alpha- and beta-secretase for the substrate APP, it is significant that the majority of Alzheimer samples tested here were low in a-secretase. Eighty percent of Alzheimer brains examined had an increase in beta-secretase, a decrease in alpha-secretase, or both; which may account for the means by which the majority of people develop Alzheimer's disease. (C) 2002 Elsevier Science (USA). All rights reserved.
引用
收藏
页码:373 / 376
页数:4
相关论文
共 50 条
  • [41] SEMAGACESTAT γ-Secretase Inhibitor Treatment of Alzheimer's Disease
    Davies, S.
    Pandian, R.
    Bolos, J.
    Castaner, R.
    DRUGS OF THE FUTURE, 2009, 34 (08) : 613 - 617
  • [42] γ-Secretase as a target for drug intervention in Alzheimer's disease
    Harrison, T
    Churcher, I
    Beher, D
    CURRENT OPINION IN DRUG DISCOVERY & DEVELOPMENT, 2004, 7 (05) : 709 - 719
  • [43] Alzheimer's Beta-Secretase in Health and Disease
    Farah, Mohamed
    Wong, Philip C.
    FASEB JOURNAL, 2008, 22
  • [44] A novel substrate for analyzing Alzheimer's disease γ-secretase
    Lichtenthaler, SF
    Multhaup, G
    Masters, CL
    Beyreuther, K
    FEBS LETTERS, 1999, 453 (03): : 288 - 292
  • [45] γ-secretase as a therapeutic target for treatment of Alzheimer's disease
    Tomita, T
    Iwatsubo, T
    CURRENT PHARMACEUTICAL DESIGN, 2006, 12 (06) : 661 - 670
  • [46] The β-Secretase BACE1 in Alzheimer's Disease
    Hampel, Harald
    Vassar, Robert
    De Strooper, Bart
    Hardy, John
    Willem, Michael
    Singh, Neeraj
    Zhou, John
    Yan, Riqiang
    Vanmechelen, Eugeen
    De Vos, Ann
    Nistico, Robert
    Corbo, Massimo
    Imbimbo, Bruno Pietro
    Streffer, Johannes
    Voytyuk, Iryna
    Timmers, Maarten
    Monfared, Amir Abbas Tahami
    Irizarry, Michael
    Albala, Bruce
    Koyama, Akihiko
    Watanabe, Naoto
    Kimura, Teiji
    Yarenis, Lisa
    Lista, Simone
    Kramer, Lynn
    Vergallo, Andrea
    BIOLOGICAL PSYCHIATRY, 2021, 89 (08) : 745 - 756
  • [47] Activation of α-secretase as an approach for treatment of Alzheimer's disease
    Fahrenholz, Falk
    Alzheimer: 100 Years and Beyond, 2006, : 255 - 259
  • [48] Turning the tide on Alzheimer's disease: modulation of γ-secretase
    Luo, Joanna E.
    Li, Yue-Ming
    CELL AND BIOSCIENCE, 2022, 12 (01):
  • [49] γ-Secretase Modulator in Alzheimer's Disease: Shifting the End
    Xia, Weiming
    Wong, Stephen T.
    Hanlon, Eugene
    Morin, Peter
    JOURNAL OF ALZHEIMERS DISEASE, 2012, 31 (04) : 685 - 696
  • [50] Emerging Alzheimer's disease therapies:: inhibition of β-secretase
    Citron, M
    NEUROBIOLOGY OF AGING, 2002, 23 (06) : 1017 - 1022